Antiatherosclerotic efficacy of policosanol, red yeast rice extract and astaxanthin in the rabbit

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 6, 2005, Pages 312-317

  Setnikar, Ivo ^a   Senin, Paolo ^a   Rovati, Lucio C ^a  

^a Rotta Research Laboratorium   (Italy)

Author keywords

Armolipid ; Astaxanthin; Atherosclerosis, experimental; Policosanol; Red yeast rice extract

Indexed keywords

ASTAXANTHIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLANT EXTRACT; POLICOSANOL; RED YEAST RICE EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; FAT INTAKE; FEMALE; HYPERLIPIDEMIA; LIPID PEROXIDATION; MONASCUS; NONHUMAN; PHYTOTHERAPY; RABBIT; TREATMENT OUTCOME;

EID: 21244477529     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296865     Document Type: Article

References (21)

1. Chen, J. T., Wesley, R., Shamburek, R. D. et al., Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stenols versus policosanol. Pharmacotherapy 25, 171 (2005)
2. FDA, Center for Food Safety and Applied Nutrition. EAFUS: EAF 3026 Astaxanthin 000472-61-7 73.35
3. Grigore, L., Redaelli, L., Maggi, F. M. et al., Armolipid, a nutritional supplement, effectively reduces plasma total and LDL cholesterol in moderate hypercholesterolemia. Drugs Affecting Lipid Metabolism. Venice, October 2004, Abstract p. 131
4. Heber, D., Lembertas, A., Lu, Q. Y. et al., An analysis of nine proprietary Chinese red rice dietary supplements: implications of variability in chemical profile and contents. J. Altern. Complement Med. 7, 133 (2001)
5. Heber, D., Yip, I., Ashely, J. M. et al., Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am. J. Clin. Nutr. 69, 231 (1999)
6. Holman, R. S., McGill, H. C. Jr., Strong, J. P. et al., Technics for studying atherosclerotic lesions. Lab. Invest. 7, 42 (1958)
7. Iwamoto, T., Hosoda, K., Hirano, R. et al., Inhibition of low-density lipoprotein oxidation by astaxanthin. J. Atheroscler. Thromb. 7, 216 (2000)
8. Mendez, R., Arruzazabala, L., Mas, R. et al., Cholesterol-lowering effects of policosanol on rabbits with hypercholesterolaemia induced by wheat starch-casein diet. Br. J. Nutr. 77, 923 (1997)
9. Menendez, R., Amor, A. M., Rodeiro, I. et al., Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch. Med. Res. 32, 8 (2001)
10. Menendez, R., Mas, R., Amor, A. M. et al., Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br. J. Clin. Pharmacol. 50, 255 (2000)
11. PDR for Nutritional Supplements, Policosanol, pp. 367-372. Thomson PDR, Montvale, NJ, USA (2001)
12. PDR for Nutritional Supplements, Red Yeast Rice, pp. 393-397. Thomson PDR, Montvale, NJ, USA (2001)
13. Poli, A., Astaxantina naturale. Integr. Nutr. 6, 23 (2003)
14. Policosanol Monograph. Alternative Med. Rev. 9, 312 (2004)
15. Prasad, K., Kalra, J., Chaudhary, A. K. et al., Effect of polymorphonuclear leukocyte derived oxygen free radicals and hypochlorous acid on cardiac function and some biochemical parameters. Am. Heart J. 119, 538 (1990)
16. Prasad, K., Kalra, J., Experimental atherosclerosis and oxygen free radicals. Angiology 40, 835 (1989)
17. Prasad, K., Kalra, J., Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of vitamin E. Am. Heart J. 125, 958 (1993)
18. Sans, S., Kestelood, H., Kromhout, D. (on behalf of the Task Force), The burden of cardiovascular diseases mortality in Europe. Task force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur. Heart J. 18, 1231 (1997)
19. Steinberg, D., Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272, 20963 (1997)
20. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur. Heart J. 24, 1601 (2003)
21. Wang, J., Lu, Z., Chi, J. et al., Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr. Ther. Res. 58, 964 (1997)